Your Messages Inbox (0) 
Your Unread Messages
See AllMost Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 4. AHA Guidelines on Cardiac CT for Assessing Coronary Artery Disease 5. Rapid correction of low vitamin D status in nursing home residents
Top Ten Searches
etanercept hypertension chf antiphospholipid fibrosis mrsa scid renal cell rickets counterpulsationYour Article Summary
Vaccination against HPV-16 oncoproteins for vulvar intraepithelial neoplasia
New England Journal of Medicine, 11/06/09
Kenter GG et al. – Clinical responses in women with HPV-16–positive, grade 3 vulvar intraepithelial neoplasia can be achieved by vaccination with a synthetic long-peptide vaccine against the HPV-16 oncoproteins E6 and E7. Complete responses appear to be correlated with induction of HPV-16–specific immunity.
Methods- Immunogenicity and efficacy of a synthetic long-peptide vaccine in women with HPV-16–positive, high-grade vulvar intraepithelial neoplasia investigated
- 20 women with HPV-16–positive, grade 3 vulvar intraepithelial neoplasia vaccinated 3 or 4 times with mix of long peptides from HPV-16 viral oncoproteins E6 and E7 in incomplete Freund's adjuvant
- End points were clinical and HPV-16–specific T-cell responses
- Most common adverse events were local swelling in 100% of patients and fever in 64% of patients
- No events exceeded grade 2 of the Common Terminology Criteria for Adverse Events of the National Cancer Institute
- At 3 months after last vaccination, 12 of 20 patients (60%; 95% confidence interval [CI], 36 to 81) had clinical responses and reported relief of symptoms
- 5 women had complete regression of lesions, and HPV-16 was no longer detectable in 4 of them
- At 12 months of follow-up, 15 of 19 patients had clinical responses (79%; 95% CI, 54 to 94), with complete response in 9 of 19 patients (47%; 95% CI, 24 to 71)
- Complete-response rate maintained at 24 months of follow-up
- All patients had vaccine-induced T-cell responses, and post hoc analyses suggested that patients with a complete response at 3 months had a significantly stronger interferon-&Upsilon–associated proliferative CD4+ T-cell response and a broad response of CD8+ interferon-&Upsilon- T cells than did patients without a complete response
Today in Women`s Health...keeping you current
Receive free subspecialty "5-minute updates" via email
Self-reported symptoms of faecal incontinence among long-term gynaecological cancer survivors and population-based controls
European Journal of Cancer, 11/23/09
Birth weight, body silhouette over the life course and incident diabetes in 91,453 middle-aged women from the French E3N cohort
Diabetes Care, 11/20/09
Bone Mineral Density and Serum Levels of Soluble Tumor Necrosis Factors, Estradiol, and Osteoprotegerin in Postmenopausal Women with Cirrhosis after Viral Hepatitis
Journal of Clinical Endocrinology and Metabolism, 11/18/09
Sponsor
Article Search
Sponsor
Sponsor